RESUMO
ETHNOPHARMACOLOGICAL RELEVANCE: Zedoary turmeric oil injection (ZTOI) extracted from the rhizome extract of Curcuma phaeocaulis Valeton, Curcuma wenyujin Y. H. Chen et C. Ling or Curcuma kwangsiensis S. G. Lee et C. F. Liang, is widely used for the treatment of virus-induced upper respiratory tract infections, peptic ulcers, viral pneumonia, etc. However, it has attracted widespread attention because it often causes adverse drug reactions (ADRs), including dyspnea. However, little is known about the mechanism underlying dyspnea caused by ZTOI, which limits its clinical application. AIM OF THE STUDY: To investigate the major pathophysiologic signatures and underlying mechanism of ZTOI-related dyspnea. METHODS: Respiratory function detection was used to explore the pathophysiologic signature of dyspnea induced by ZTOI. UV-vis absorption spectroscopy and isothermal titration calorimetry were applied to test the interaction between ZTOI and hemoglobin (Hb). GCâMS was used to identify the main components in ZTOI. Molecular docking, surface plasmon resonance, and circular dichroism spectroscopy were employed to test the reaction between ß-elemene and Hb. Western blot was performed to investigate the effect of ß-elemene on the hypoxia signaling pathway. RESULTS: The results showed that ZTOI-induced dyspnea was related to a decreased oxygen carrying capacity of Hb. The molecular interaction between ZTOI and Hb was proven. Notably, ß-elemene in ZTOI exhibited high binding affinity to Hb and altered its secondary structure. Furthermore, it was found that ß-elemene downregulated the expression of prolyl hydroxylase-domain protein 2 and upregulated the expression of hypoxia-inducible factor-1α. CONCLUSIONS: Our study is valuable for better understanding the pathophysiological characteristics and underlying mechanism of ZTOI to ensure its safe clinical application. We also provided a strategy to elucidate the underlying mechanism based on inspiration from clinical ADR phenotypes for investigating other medical products with ADRs in the clinic.
Assuntos
Curcuma , Sesquiterpenos , Humanos , Curcuma/química , Subunidade alfa do Fator 1 Induzível por Hipóxia , Simulação de Acoplamento Molecular , Sesquiterpenos/farmacologia , Sesquiterpenos/química , Hemoglobinas , Dispneia/induzido quimicamente , Dispneia/tratamento farmacológicoRESUMO
BACKGROUND: Corona virus disease 2019 (COVID-19) has spread around the world since its outbreak, and there is no ascertained effective drug up to now. Lianhua Qingwen (LHQW) has been widely used in China and overseas Chinese, which had some advantages in the treatment of COVID-19. OBJECTIVE: To evaluate the efficacy and safety of LHQW for COVID-19 by conducting a systematic review with meta-analysis. METHODS: A comprehensive literature search was conducted in 12 electronic databases from their establishment to October 30, 2021. Note Express 3.2.0 was used for screening of trials, and the data was independently extracted in duplicate by 2 researchers. The risk of bias of randomized controlled trials (RCTs) and retrospective studies were assessed by using the Cochrane collaboration tool and Newcastle Ottawa Scale, respectively, followed by data analysis using RevMan 5.3. The RCTs or retrospective studies to treat COVID-19 using LHQW were included. The intervention measures in the experimental group were LHQW alone or combined with chemical drugs (LCWC), and that in the control group were chemical drugs (CDs). Outcome measures included computed tomography (CT) recovery rate, disappearance rates of primary (fever, cough, fatigue), respiratory, gastrointestinal and other symptoms, exacerbation rate and adverse reaction. Subgroup analysis was conducted according to whether LHQW was combined with CDs and the different treatment methods in the control group. RESULTS: Nine trials with 1,152 participants with COVID-19 were included. The CT recovery rates of LHQW and LCWC were 1.36 and 1.32 times of CDs, respectively (P<0.05). Compared with CDs, LCWC remarkably increased the disappearance rates of fever, cough, fatigue, expectoration, shortness of breath, and muscle soreness (P<0.05). LHQW also obviously decreased the exacerbation rate, which was 0.45 times of CDs alone (P<0.05). There was no obvious difference between LCWC and CDs in adverse reaction (P>0.05). CONCLUSIONS: LHQW was more suitable for treating COVID-19 patients with obvious expectoration, shortness of breath and muscle soreness. LHQW had advantages in treating COVID-19 with no obvious exacerbation. (PROSPERO No. CRD42021235937).
Assuntos
Tratamento Farmacológico da COVID-19 , Medicamentos de Ervas Chinesas , Tosse/tratamento farmacológico , Medicamentos de Ervas Chinesas/efeitos adversos , Dispneia/induzido quimicamente , Dispneia/tratamento farmacológico , Fadiga/tratamento farmacológico , Humanos , Mialgia/induzido quimicamente , Mialgia/tratamento farmacológicoRESUMO
Because there is a solid pharmacological rationale based on positive interactions between long-acting muscarinic receptor antagonists (LAMAs) and long-acting ß-agonists (LABAs) for their ability to relax human airway smooth muscle in vitro alongside several randomised controlled trials (RCTs) and real-world observational studies that support the use of LAMA/LABA fixed-dose combinations (FDCs) for the treatment of patients with chronic obstructive pulmonary disease (COPD), in this narrative review we discuss the preclinical and clinical proofs supporting the use of LAMA + LABA therapy in COPD and why this therapeutic approach optimises bronchodilation. Robust evidence indicates that all LAMA/LABA FDCs are consistently more effective than LAMA or LABA administered alone in improving lung function, dyspnoea, quality of life and exercise capacity in patients with COPD. However, the ability of dual bronchodilation with FDCs of LAMA/LABA to prevent or reduce the risk of COPD exacerbations remains unclear due to conflicting data from large RCTs, despite several mechanisms explaining why such combinations should be of value in decreasing the frequency of COPD exacerbations. Both LABAs and LAMAs mechanistically can affect the cardiovascular system, but from clinical studies to date, LAMA/LABA FDCs have an acceptable cardiovascular safety profile, at least in the COPD population enrolled in RCTs. Indirect evidence suggests that some FDCs may even exert a protective role against serious cardiovascular adverse events compared to monotherapies. Consequently, several LAMA/LABA FDCs have been developed and approved for clinical use as treatments for patients with COPD. However, to date, there are unfortunately very few head-to-head studies comparing the safety and efficacy of different LAMA/LABA FDCs, making it difficult to choose the most appropriate combination, although the use of meta-analyses has provided some information in this regard. Endurance time Exercise time until exhaustion measured by a standard endurance test. Inspiratory capacity The maximum volume of air that can be inspired after reaching the end of a normal, quiet expiration. It is the sum of the tidal volume and the inspiratory reserve volume. St George's Respiratory Questionnaire (SGRQ) A tool to measure health status in patients with respiratory disease. It has three domains: symptoms, activity and impacts. A total score is also calculated. A minimal important difference (range) of â¼4 (2.4-5.6) units in the SGRQ total score is supported by published studies. Surface under the cumulative ranking curve analysis (SUCRA) A numerical representation of the overall rating that displays a single value for each treatment. SUCRA levels vary from 0% to 100%. The higher the SUCRA value and the closer it is to 100%, the more likely therapy is in the top rank or one of the top rankings; the lower the SUCRA value and the closer it is to 0%, the more likely therapy is in the bottom rank or one of the bottom ranks. Transition dyspnoea index (TDI) Widely used in clinical studies of COPD to measure shortness of breath, indicating change in response to an intervention. The total score ranges from -9 to 9; the negative value indicates deterioration, whereas a positive value indicates improvement. There is sufficient evidence to suggest that the minimal important difference for the TDI score is 1 unit. Trough FEV1 The mean volume of air that can be forced out in 1 second approximately 12 (with a twice-daily agent) or 24 (with a once-daily agent) hours after the last administration of bronchodilator.
Assuntos
Agonistas de Receptores Adrenérgicos beta 2 , Antagonistas Muscarínicos , Doença Pulmonar Obstrutiva Crônica , Administração por Inalação , Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Broncodilatadores , Combinação de Medicamentos , Dispneia/induzido quimicamente , Humanos , Antagonistas Muscarínicos/uso terapêutico , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Resultado do TratamentoRESUMO
Zedoary turmeric oil (ZTO) has been widely used in clinic. However, the unpleasant induced dyspnoea inevitably impedes its clinical application. Thus, it is urgent to elucidate the mechanism underlying the ZTO-induced dyspnoea. In this study, network pharmacology was firstly performed to search the clue of ZTO-induced dyspnoea. The key target genes of ZTO-induced dyspnoea were analysed using GO enrichment analysis and KEGG pathway analysis. GO analysis suggested that haem binding could be a key molecular function involved in ZTO-induced dyspnoea. Hence, the haemoglobin (Hb) was focused for its oxygen-carrying capacity with haem as its critical component binding to the oxygen. Ultraviolet-visible absorption spectrum indicated that the ZTO injection (ZTOI) perturbed the Soret band of Hb, suggesting an interaction between ZTO and Hb. GC-MS analysis revealed that ß-elemene, germacrone, curdione and furanodiene were main components of ZTOI. Molecular docking was used to illustrate the high affinity between representative sesquiterpenes and Hb, which was finally confirmed by surface plasmon resonance, suggesting their potential roles in dyspnoea by ZTO. Following a network pharmacology-driven strategy, our study revealed an intervened Hb-based mechanism underlying the ZTO-induced dyspnoea, providing a reference for elucidating mechanism underlying adverse drug reactions of herbal medicines in clinic.
Assuntos
Curcuma , Medicamentos de Ervas Chinesas , Curcuma/química , Dispneia/induzido quimicamente , Heme , Simulação de Acoplamento Molecular , Farmacologia em Rede , OxigênioRESUMO
Alchornea cordifolia is known to be a plant with a variety of medicinal properties and is quoted by many traditional healers to treat a variety of medicinal problems in the Democratic Republic of Congo. However, very little is known about its potential toxicity. We report the case of a 9-year-old boy referred for assessment of suspected bronchial troubles without a history of atopic disease or drug allergy who developed dyspnea, dysphagia, asthenia and lingual ulcers within 30 minutes after nasal and oral administration of decoction of palm oil associated with A. cordifolia leaves in water. In the present report, adverse effects of A. cordifolia therapy may be related to the mixtures of active compounds that they contain and can cause the symptoms observed in our patient. These findings call for caution in the use of A. cordifolia especially in children.
Assuntos
Euphorbiaceae/química , Óleo de Palmeira/efeitos adversos , Extratos Vegetais/efeitos adversos , Administração Oral , Astenia/induzido quimicamente , Criança , Transtornos de Deglutição/induzido quimicamente , Dispneia/induzido quimicamente , Humanos , Masculino , Úlceras Orais/induzido quimicamente , Óleo de Palmeira/administração & dosagem , Extratos Vegetais/administração & dosagem , Folhas de PlantaRESUMO
RATIONALE: Obliterative bronchiolitis in former coffee workers prompted a cross-sectional study of current workers. Diacetyl and 2,3-pentanedione levels were highest in areas for flavoring and grinding/packaging unflavored coffee. METHODS: We interviewed 75 (88%) workers, measured lung function, and created exposure groups based on work history. We calculated standardized morbidity ratios (SMRs) for symptoms and spirometric abnormalities. We examined health outcomes by exposure groups. RESULTS: SMRs were elevated 1.6-fold for dyspnea and 2.7-fold for obstruction. The exposure group working in both coffee flavoring and grinding/packaging of unflavored coffee areas had significantly lower mean ratio of forced expiratory volume in 1 s to forced vital capacity and percent predicted mid-expiratory flow than workers without such exposure. CONCLUSION: Current workers have occupational lung morbidity associated with high diacetyl and 2,3-pentanedione exposures, which were not limited to flavoring areas.
Assuntos
Bronquiolite Obliterante/induzido quimicamente , Café/química , Indústria de Processamento de Alimentos , Doenças Profissionais/induzido quimicamente , Exposição Ocupacional/efeitos adversos , Adulto , Obstrução das Vias Respiratórias/induzido quimicamente , Bronquiolite Obliterante/epidemiologia , Bronquiolite Obliterante/fisiopatologia , Estudos Transversais , Diacetil/análise , Diacetil/toxicidade , Dispneia/induzido quimicamente , Feminino , Aromatizantes/análise , Volume Expiratório Forçado , Humanos , Pulmão/fisiopatologia , Masculino , Doenças Profissionais/epidemiologia , Doenças Profissionais/fisiopatologia , Exposição Ocupacional/análise , Pentanonas/análise , Pentanonas/toxicidade , Respiração , Espirometria , Capacidade Vital , Local de TrabalhoRESUMO
OBJECTIVES: Pepper (oleoresin capsicum) spray is one of the most common riot-control measures used today. Although not lethal, exposure of pepper spray can cause injury to different organ systems. This review aimed to summarise the major clinicopathological effects of pepper spray in humans. DATA SOURCES: MEDLINE, EMBASE database, and Cochrane Database of Systematic Reviews were used to search for terms associated with the clinicopathological effects of pepper spray in humans and those describing the pathophysiology of capsaicin. A phone interview with two individuals recently exposed to pepper spray was also conducted to establish clinical symptoms. STUDY SELECTION: Major key words used for the MEDLINE search were "pepper spray", "OC spray", "oleoresin capsicum"; and other key words as "riot control agents", "capsaicin", and "capsaicinoid". We then combined the key words "capsaicin" and "capsaicinoid" with the major key words to narrow down the number of articles. A search with other databases including EMBASE and Cochrane Database of Systematic Reviews was also conducted with the above phrases to identify any additional related articles. DATA EXTRACTION: All article searches were confined to human study. The bibliography of articles was screened for additional relevant studies including non-indexed reports, and information from these was also recorded. Non-English articles were included in the search. DATA SYNTHESIS: Fifteen articles were considered relevant. Oleoresin capsicum causes almost instantaneous irritative symptoms to the skin, eyes, and respiratory system. Dermatological effects include a burning sensation, erythema, and hyperalgesia. Ophthalmic effects involve blepharospasm, conjunctivitis, peri-orbital oedema, and corneal pathology. Following inhalation, a stinging or burning sensation can be felt in the nose with sore throat, chest tightness, or dyspnoea. The major pathophysiology is neurogenic inflammation caused by capsaicinoid in the pepper spray. There is no antidote for oleoresin capsicum. Treatment consists of thorough decontamination, symptom-directed supportive measures, and early detection and treatment of systemic toxicity. Decontamination should be carefully carried out to avoid contamination of the surrounding skin and clothing. CONCLUSION: Pepper (oleoresin capsicum) spray is an effective riot-control agent and does not cause life-threatening clinical effects in the majority of exposed individuals. Early decontamination minimises the irritant effects.
Assuntos
Inflamação Neurogênica/induzido quimicamente , Extratos Vegetais/toxicidade , Substâncias para Controle de Distúrbios Civis/toxicidade , Aerossóis , Descontaminação , Dispneia/induzido quimicamente , Oftalmopatias/induzido quimicamente , Humanos , Exposição por Inalação/efeitos adversos , Nariz/efeitos dos fármacos , Faringite/induzido quimicamente , Dermatopatias/induzido quimicamenteRESUMO
Acute kidney injury (AKI) is one of the complications of hematopoietic stem cell transplantation and is associated with increased mortality. N-acetylcysteine (NAC) is a thiol compound with antioxidant and vasodilatory properties that has been investigated for the prevention of AKI in several clinical settings. In the present study, we evaluated the effects of intravenous NAC on the prevention of AKI in allogeneic hematopoietic stem cell transplantation patients. A double-blind randomized placebo-controlled trial was conducted, and 80 patients were recruited to receive 100 mg/kg/day NAC or placebo as intermittent intravenous infusion from day -6 to day +15. AKI was determined on the basis of the Risk-Injury-Failure-Loss-End-stage renal disease and AKI Network criteria as the primary outcome. We assessed urine neutrophil gelatinase-associated lipocalin (uNGAL) on days -6, -3, +3, +9 and +15 as the secondary outcome. Moreover, transplant-related outcomes and NAC adverse reactions were evaluated during the study period. Statistical analysis was performed using appropriate parametric and non-parametric methods including Kaplan-Meier for AKI and generalized estimating equation for uNGAL. At the end of the trial, data from 72 patients were analysed (NAC: 33 patients and placebo: 39 patients). Participants of each group were not different considering baseline characteristics. AKI was observed in 18% of NAC recipients and 15% of placebo group patients, and the occurrence pattern was not significantly different (p = 0.73). Moreover, no significant difference was observed between groups for uNGAL measures (p = 0.10). Transplant-related outcomes were similar for both groups, and all patients had successful engraftment. Three patients did not tolerate NAC because of abdominal pain, shortness of breath and rash with pruritus and were dropped from the intervention group before transplantation. However, the frequency of adverse reactions was not significantly different between groups. In conclusion, our findings could not show any clinical benefits from high-dose NAC particularly for AKI prevention in allogeneic hematopoietic stem cell transplantation patients.
Assuntos
Acetilcisteína/uso terapêutico , Injúria Renal Aguda/prevenção & controle , Antioxidantes/uso terapêutico , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Vasodilatadores/uso terapêutico , Dor Abdominal/induzido quimicamente , Acetilcisteína/administração & dosagem , Acetilcisteína/efeitos adversos , Injúria Renal Aguda/etiologia , Adulto , Aloenxertos , Antioxidantes/administração & dosagem , Antioxidantes/efeitos adversos , Método Duplo-Cego , Toxidermias/etiologia , Dispneia/induzido quimicamente , Feminino , Sobrevivência de Enxerto , Doença Enxerto-Hospedeiro/prevenção & controle , Neoplasias Hematológicas/terapia , Humanos , Terapia de Imunossupressão , Infusões Intravenosas , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Prurido/induzido quimicamente , Condicionamento Pré-Transplante , Vasodilatadores/administração & dosagem , Vasodilatadores/efeitos adversos , Adulto JovemRESUMO
OBJECTIVE: 2,4-Dinitrophenol (DNP) increases energy consumption by uncoupling oxidative phosphorylation. Although not licensed as a medicine, it is sometimes used by 'body sculptors' and for weight loss as a 'fat burning' agent. This research was performed to characterise patterns of presentation, clinical features and outcomes of patients reported to the National Poisons Information Service (NPIS) in the UK after exposure to DNP. METHODS: NPIS telephone enquiry records and user sessions for TOXBASE, the NPIS online information database, related to DNP, were reviewed from 1 January 2007 to 31 December 2013. RESULTS: Of the 30 separate systemic exposures to DNP reported by telephone to NPIS during the study period (27 males, 3 females, with a median age of 23.5â years), there were 3 during 2007-2011 (inclusive), 5 during 2012 and 22 during 2013. TOXBASE user sessions also increased sharply from 6 in 2011 to 35 in 2012 and 331 in 2013. The modes of exposure reported in telephone enquiries were chronic (n=2), acute (n=12) and subacute (n=16). Commonly reported clinical features were fever (47%), tachycardia (43%), sweating (37%), nausea or vomiting (27%), skin discolouration or rash (23%), breathing difficulties (23%), abdominal pain (23%), agitation (13%) and headache (13%). There were five (17%, 95% CI 6.9% to 34%) fatalities, four involving acute overdose. CONCLUSIONS: The study indicates a substantial recent increase in clinical presentations with toxicity caused by exposure to DNP in the UK with an associated high mortality. Further steps are needed to warn potential users of the severe and sometimes fatal toxicity that may occur after exposure to this compound.
Assuntos
2,4-Dinitrofenol/efeitos adversos , Suplementos Nutricionais/efeitos adversos , 2,4-Dinitrofenol/intoxicação , Dor Abdominal/induzido quimicamente , Adolescente , Adulto , Acatisia Induzida por Medicamentos , Criança , Suplementos Nutricionais/intoxicação , Dispneia/induzido quimicamente , Exantema/induzido quimicamente , Feminino , Febre/induzido quimicamente , Cefaleia/induzido quimicamente , Humanos , Masculino , Náusea/induzido quimicamente , Centros de Controle de Intoxicações , Sudorese/efeitos dos fármacos , Taquicardia/induzido quimicamente , Reino Unido , Vômito/induzido quimicamente , Adulto JovemRESUMO
Forty-year-old man was admitted to emergency department with complains of chest pain and dispnea after exposure the pepper gas that sprayed to environment during a social event. Physical examination and electrocardiogram was revealed acute myocardial infarction.
Assuntos
Infarto do Miocárdio/induzido quimicamente , Extratos Vegetais/efeitos adversos , Gases Lacrimogênios/efeitos adversos , Adulto , Dor no Peito/induzido quimicamente , Angiografia Coronária , Dispneia/induzido quimicamente , Eletrocardiografia , Hemodinâmica/fisiologia , Humanos , Masculino , Infarto do Miocárdio/diagnóstico por imagemRESUMO
Recent studies suggest that in utero exposure of methyl donors influences programming of the fetal immune system in favor of development of allergic disease. The aim of this study was to assess whether the MTHFR C677T polymorphism, folic acid supplementation, and circulating folate and vitamin B-12 concentrations during pregnancy were associated with wheezing, shortness of breath, and atopic dermatitis in offspring. The study was a population-based birth cohort from fetal life until 48 mo (n = 8742). The use of folic acid supplementation during pregnancy was assessed by questionnaire. Plasma folate and serum vitamin B-12 concentrations and the MTHFR C677T polymorphism were available from blood collected in early pregnancy. Atopic dermatitis, wheezing, and shortness of breath in the offspring were assessed by parental-derived questionnaires at 12, 24, 36, and 48 mo. Maternal folate >16.2 nmol/L and vitamin B-12 >178 pmol/L were positively associated with the development of atopic dermatitis [adjusted OR: 1.18 (95% CI: 1.05-1.33) and adjusted OR: 1.30 (95% CI: 1.06-1.60) for the highest quartiles of folate and vitamin B-12 concentrations, respectively] but not with wheezing and shortness of breath. Maternal MTHFR C677T polymorphism and folic acid supplementation were not associated with wheezing, shortness of breath, and atopic dermatitis. No interactions were found by age, family history of atopy, folic acid supplementation, MTHFR C677T polymorphism, or maternal smoking (P-interaction > 0.10). High folate and vitamin B-12 levels during pregnancy are associated with increased prevalence of atopic dermatitis in the offspring. Potential risks of high folate and vitamin B-12 concentrations on allergic outcomes should be evaluated when discussing mandatory fortification programs.
Assuntos
Dermatite Atópica/etiologia , Ácido Fólico/sangue , Fenômenos Fisiológicos da Nutrição Materna , Primeiro Trimestre da Gravidez/sangue , Vitamina B 12/sangue , Desenvolvimento Infantil , Estudos de Coortes , Dermatite Atópica/induzido quimicamente , Dermatite Atópica/epidemiologia , Dermatite Atópica/genética , Suplementos Nutricionais/efeitos adversos , Dispneia/induzido quimicamente , Dispneia/epidemiologia , Dispneia/etiologia , Dispneia/genética , Feminino , Ácido Fólico/efeitos adversos , Seguimentos , Alimentos Fortificados/efeitos adversos , Humanos , Recém-Nascido , Masculino , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Países Baixos/epidemiologia , Polimorfismo de Nucleotídeo Único , Gravidez , Prevalência , Estudos Prospectivos , Sons Respiratórios/etiologia , Sons Respiratórios/genética , Vitamina B 12/efeitos adversosRESUMO
OBJECTIVE: To discuss phytopharmacological potential and anti-asthmatic activity of Ficus religiosa (F. religiosa) (L.). METHODS: Fresh leaves of F. religiosa were obtained from Vastrapur Lake, Ahmedabad, and dried to obtain powder. Histamine and acetylcholine were used to guinea pigs to establish bronchospasm model. In in vivo study, the aqueous extract of F. religiosa leaves (AEFR) at doses of 150 and 300 mg/kg was administrated to guinea pigs, and the broncho-protective activity of AEFR was compared with aminophylline at 25 mg/kg. While in in vitro study, and 10 g/mL, 20 g/mL, 30 g/mL of AEFRL was administrated to guinea pigs, respectively, and mast cell stabilizing activity of AEFR was compared with ketotifen at 10 g/mL. RESULTS: In the in-vivo model, pre-treatment with aminophylline (25 mg/kg, ip.) could significantly delay the onset of histamine induced pre-convulsive dyspnea, compared with vehicle control. Administration of AEFRL (150 and 300 mg/kg, ip.) also produced significant effect on latency to develop histamine & acetylcholine induced pre-convulsive dyspnea. In the mast cell stabilizing model, AEFRL at 10, 20 and 30 µg/mL could significantly increase the number of intact cells. CONCLUSIONS: It can be concluded that AEFRL is effective on histamine & acetylcholine induced bronchospasm in guinea pigs. In addition, AEFRL can potentiate the number of intact cells in the mast cell stabilizing model.
Assuntos
Antialérgicos/farmacologia , Antiasmáticos/farmacologia , Asma/tratamento farmacológico , Espasmo Brônquico/tratamento farmacológico , Dispneia/tratamento farmacológico , Ficus/química , Fitoterapia/métodos , Extratos Vegetais/farmacologia , Acetilcolina/efeitos adversos , Aminofilina/farmacologia , Animais , Antialérgicos/uso terapêutico , Antiasmáticos/uso terapêutico , Asma/fisiopatologia , Espasmo Brônquico/induzido quimicamente , Espasmo Brônquico/fisiopatologia , Degranulação Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Dispneia/induzido quimicamente , Dispneia/fisiopatologia , Feminino , Cobaias , Histamina/efeitos adversos , Cetotifeno/farmacologia , Masculino , Mastócitos/efeitos dos fármacos , Extratos Vegetais/uso terapêutico , Folhas de Planta/química , RatosRESUMO
BACKGROUND: Oxaliplatin in combination with either 5-fluorouracil or capecitabine is commonly used in the treatment of colorectal cancer and is rarely associated with pulmonary toxicity. This is the first reported case of oxaliplatin and capecitabine/5-fluorouracil causing pulmonary toxicity in a patient with pre-existing asymptomatic interstitial lung disease. CASE REPORT: We report a case of a man who was treated with oxaliplatin and capecitabine for 1 cycle, then subsequently with oxaliplatin and 5-fluorouracil following a resected Dukes' C colon carcinoma. His preoperative computed tomography scan incidentally showed mild pulmonary interstitial changes for which he was asymptomatic. He developed pulmonary fibrosis during the course of his chemotherapy, and therefore further chemotherapy was stopped. He was treated with high dose steroids and immunosuppressants which initially stabilized his respiratory symptoms. CONCLUSIONS: Pulmonary fibrosis is a rare complication of oxaliplatin and capecitabine/5-fluorouracil. With the widespread use of oxaliplatin combinations in colorectal cancer, active assessment for interstitial lung disease is recommended and caution in its use should be exercised in those with pre-existing interstitial lung disease.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/toxicidade , Pulmão/efeitos dos fármacos , Neoplasias/tratamento farmacológico , Fibrose Pulmonar/induzido quimicamente , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Capecitabina , Quimioterapia Adjuvante , Colectomia , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Desoxicitidina/toxicidade , Esquema de Medicação , Dispneia/induzido quimicamente , Fluoruracila/administração & dosagem , Fluoruracila/análogos & derivados , Fluoruracila/toxicidade , Humanos , Pulmão/diagnóstico por imagem , Doenças Pulmonares Intersticiais/complicações , Doenças Pulmonares Intersticiais/diagnóstico por imagem , Medidas de Volume Pulmonar , Masculino , Neoplasias/cirurgia , Compostos Organoplatínicos/administração & dosagem , Compostos Organoplatínicos/toxicidade , Oxaliplatina , Fibrose Pulmonar/diagnóstico por imagem , Tomografia Computadorizada por Raios XRESUMO
We report the occurrence of serious reactions after treatment with oral ivermectin in two patients with Mansonella ozzardi infections. Both had systemic and respiratory symptoms and recovered without sequelae. Follow-up revealed clearance of microfilaremia in both cases, with relapse in one of them. These reactions are well described in the treatment of other filarial infections, but have not yet been reported in the treatment of M. ozzardi. We are now reporting the first such known reactions with this helminthiasis.
Assuntos
Calafrios/induzido quimicamente , Dispneia/induzido quimicamente , Febre/induzido quimicamente , Filaricidas/efeitos adversos , Ivermectina/efeitos adversos , Mansonella , Mansonelose/tratamento farmacológico , Parasitemia/tratamento farmacológico , Idoso , Animais , Argentina , Terapia Combinada , Feminino , Filaricidas/uso terapêutico , Humanos , Ivermectina/uso terapêutico , Masculino , Mansonella/efeitos dos fármacos , Mansonelose/parasitologia , Microfilárias/efeitos dos fármacos , Parasitemia/parasitologia , Fitoterapia , RecidivaAssuntos
Embolia Aérea/induzido quimicamente , Produtos Domésticos/intoxicação , Peróxido de Hidrogênio/intoxicação , Oxidantes/intoxicação , Veia Porta/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Dor Abdominal/induzido quimicamente , Adulto , Overdose de Drogas , Dispneia/induzido quimicamente , Embolia Aérea/diagnóstico por imagem , Embolia Aérea/terapia , Feminino , Humanos , Oxigenoterapia Hiperbárica , Oxigenoterapia , Tentativa de Suicídio , Resultado do TratamentoRESUMO
BACKGROUND: Vicks VapoRub (VVR) [Proctor and Gamble; Cincinnati, OH] is often used to relieve symptoms of chest congestion. We cared for a toddler in whom severe respiratory distress developed after VVR was applied directly under her nose. We hypothesized that VVR induced inflammation and adversely affected mucociliary function, and tested this hypothesis in an animal model of airway inflammation. METHODS: [1] Trachea specimens excised from 15 healthy ferrets were incubated in culture plates lined with 200 mg of VVR, and the mucin secretion was compared to those from controls without VVR. Tracheal mucociliary transport velocity (MCTV) was measured by timing the movement of 4 microL of mucus across the trachea. Ciliary beat frequency (CBF) was measured using video microscopy. [2] Anesthetized and intubated ferrets inhaled a placebo or VVR that was placed at the proximal end of the endotracheal tube. We evaluated both healthy ferrets and animals in which we first induced tracheal inflammation with bacterial endotoxin (a lipopolysaccharide [LPS]). Mucin secretion was measured using an enzyme-linked lectin assay, and lung water was measured by wet/dry weight ratios. RESULTS: [1] Mucin secretion was increased by 63% over the controls in the VVR in vitro group (p < 0.01). CBF was decreased by 35% (p < 0.05) in the VVR group. [2] Neither LPS nor VVR increased lung water, but LPS decreased MCTV in both normal airways (31%) and VVR-exposed airways (30%; p = 0.03), and VVR increased MCTV by 34% in LPS-inflamed airways (p = 0.002). CONCLUSIONS: VVR stimulates mucin secretion and MCTV in the LPS-inflamed ferret airway. This set of findings is similar to the acute inflammatory stimulation observed with exposure to irritants, and may lead to mucus obstruction of small airways and increased nasal resistance.
Assuntos
Dispneia/induzido quimicamente , Mucinas/efeitos dos fármacos , Mucinas/metabolismo , Depuração Mucociliar/efeitos dos fármacos , Extratos Vegetais/farmacologia , Terpenos/farmacologia , Traqueia/efeitos dos fármacos , Animais , Cílios/efeitos dos fármacos , Modelos Animais de Doenças , Combinação de Medicamentos , Feminino , Furões , Humanos , Lactente , Extratos Vegetais/efeitos adversos , Mucosa Respiratória/efeitos dos fármacos , Mucosa Respiratória/metabolismo , Mucosa Respiratória/fisiopatologia , Infecções Respiratórias/complicações , Infecções Respiratórias/tratamento farmacológico , Infecções Respiratórias/fisiopatologia , Terpenos/efeitos adversos , Traqueia/metabolismo , Traqueia/fisiopatologiaRESUMO
The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin. Oxaliplatin improves the efficacy of this combination in patients with stage III colon cancer and moreover its toxicity is well tolerable. We describe a rare clinical case of acute dyspnoea probably related to oxaliplatin at one month from the end of the adjuvant treatment. A 74-year-old man developed a locally advanced sigmoid carcinoma (pT3N1M0). A port a cath attached to an open-ended catheter was implanted in order to administer primary chemotherapy safely according to the FOLFOX4 schedule. One month following the end of the 6th cycle, the patient referred a persistent cough and moderate dyspnoea. Chest radiography displayed a change in the lung interstitium, chest CT scan confirmed this aspect of adult respiratory distress syndrome, spirometry reported a decreased carbon monoxide diffusion capacity. Antibiotic and corticosteroids were administered for 10 d, then a repeated chest X ray evidenced a progressive pulmonary infiltration. A transbronchial biopsy and cytology did not show an infective process, a CT scan reported radiological abnormalities including linear and nodular densities which were becoming confluents. Antimicotic and antiviral drugs did not evidence any benefit. The antiviral therapy was stopped and high dose metilprednisolone was started. The patient died of pulmonary distress after 10 d.
Assuntos
Antineoplásicos/efeitos adversos , Dispneia/induzido quimicamente , Compostos Organoplatínicos/efeitos adversos , Doença Aguda , Idoso , Antineoplásicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias do Colo/tratamento farmacológico , Dispneia/diagnóstico , Fluoruracila/administração & dosagem , Humanos , Leucovorina/administração & dosagem , Masculino , Compostos Organoplatínicos/administração & dosagem , OxaliplatinaRESUMO
Fifty consecutive new cardiology clinic patients who were on statin drug therapy (for an average of 28 months) on their initial visit were evaluated for possible adverse statin effects (myalgia, fatigue, dyspnea, memory loss, and peripheral neuropathy). All patients discontinued statin therapy due to side effects and began supplemental CoQ(10) at an average of 240 mg/day upon initial visit. Patients have been followed for an average of 22 months with 84% of the patients followed now for more than 12 months. The prevalence of patient symptoms on initial visit and on most recent follow-up demonstrated a decrease in fatigue from 84% to 16%, myalgia from 64% to 6%, dyspnea from 58% to 12%, memory loss from 8% to 4% and peripheral neuropathy from 10% to 2%. There were two deaths from lung cancer and one death from aortic stenosis with no strokes or myocardial infarctions. Measurements of heart function either improved or remained stable in the majority of patients. We conclude that statin-related side effects, including statin cardiomyopathy, are far more common than previously published and are reversible with the combination of statin discontinuation and supplemental CoQ(10). We saw no adverse consequences from statin discontinuation.
Assuntos
Anticolesterolemiantes/efeitos adversos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Ubiquinona/análogos & derivados , Adulto , Idoso , Idoso de 80 Anos ou mais , Cardiomiopatias/induzido quimicamente , Cardiomiopatias/tratamento farmacológico , Coenzimas , Dispneia/induzido quimicamente , Dispneia/tratamento farmacológico , Fadiga/induzido quimicamente , Fadiga/tratamento farmacológico , Feminino , Seguimentos , Humanos , Masculino , Transtornos da Memória/induzido quimicamente , Transtornos da Memória/tratamento farmacológico , Pessoa de Meia-Idade , Doenças Musculares/induzido quimicamente , Doenças Musculares/tratamento farmacológico , Dor/induzido quimicamente , Dor/tratamento farmacológico , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Estudos Prospectivos , Ubiquinona/uso terapêuticoRESUMO
BACKGROUND: Toxicity secondary to rectally administered hypertonic phosphate solution in patients with normal renal function is rarely reported in the literature. We report a case of electrolyte disturbance and seizure secondary to the rectal administration of 2 Fleet pediatric enemas. CASE REPORT: A 4-year-old white female with spinal muscular atrophy and chronic constipation was brought to the emergency department with complaints of lethargy and difficulty breathing following the administration of 2 Fleet pediatric enemas. In the emergency department, physical examination was significant for a depressed level of consciousness and shallow respirations. A basic metabolic profile was significant for a calcium of 3.3 mg/dL, phosphate of 23 mg/dL, and sodium of 153 mEq/L. Arterial blood gases revealed a pH of 7.24, Pco2 of 38 mm Hg, Po2 of 220 mm Hg. Electrocardiogram revealed a prolonged QT interval of 340 milliseconds with a corrected QT interval of 498 milliseconds. Sixteen hours postexposure, she experienced a generalized seizure unresponsive to multiple doses of lorazepam and responsive only to 100 mg of intravenous calcium chloride. Two days after presentation, the patient experienced complete resolution of symptoms. CONCLUSION: Osmotically acting hypertonic phosphate enemas can result in severe toxicity if retained. This is true even in patients without predisposing risk factors.